ArticleNature communications2025
Cu/Zn/histidine supramolecular assemblies with optimized Cu catalytic sites as an alternative of superoxide dismutase.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Engineering of Artificial Antioxidase Enables Boosted Catalytic Activity in Inflammatory Bowel Disease Alleviation.Angewandte Chemie (International ed. in English) · 2026Article
- Deciphering the Catalytic Mechanism of Oxidoreductase-Like Nanozymes Along the Reaction Pathway: Activity, Specificity and Sustainability.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Antimicrobial Nanozymes: Structure-Activity-Guided Design, Synergy, and Applications.Research (Washington, D.C.) · 2026Review
- Oxidoreductase-Like Nanozymes: From Biosensing to Molecular Mechanisms in Disease Therapy.International journal of nanomedicine · 2026Review
- Exogenous Pyrroloquinoline Quinone Application Enhances Low-Phosphorus Adaptation in Rice by Modulating Redox Homeostasis Under Variable Light.Physiologia plantarumArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Superoxide dismutase (SOD), featured with unique metal catalytic sites, is the first defense against reactive oxygen species (ROS) damage in vivo and well used in the treatment of oxidative stress-related diseases. However, the catalytic activity of natural SOD is limited by the metal ion coordination with rigid amino-acid residues. Inspired by the Cu
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.